<unk> , sold under the brand names Lumakras and Lumykras, is an anti-cancer medication used to treat non-small-cell lung cancer (NSCLC). It targets a specific mutation, G12C, in the protein KRAS which is responsible for various forms of cancer. The most common side effects include diarrhea, musculoskeletal pain, nausea, fatigue, liver damage and cough.<unk>  is an inhibitor of the RAS GTPase family.<unk>  is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for approximately 25% of mutations in non-small cell lung cancers. KRAS G12C mutations represent about 13% of mutations in non-small cell lung cancers.<unk>  was approved for medical use in the United States in May 2021.
Sotorasib
Belinostat
Tezacaftor
Alpelisib
Umbralisib
Corbevax
Zantac
Snoezelen